NFKB1 and primary biliary cholangitis: BAHD1 inhibits the NF-κB pathway to decrease pro-inflammatory cytokines, and since sustained intrahepatic NF-κB activation in PBC drives massive pro-inflammatory factor release (Zhu et al., 2015), it may act via this pathway inhibition.